Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments

H. Lundbeck A/S (CPH: LUN) has presented six-month interim data from its 12-month real-world INFUSE study evaluating Vyepti (eptinezumab) in adults with migraine who had previously failed at least one preventive anti-CGRP therapy. The results, shared at the 2026 Headache Cooperative of the Pacific Annual Conference, point to significant improvements in monthly headache days and other patient-reported outcomes, highlighting Vyepti’s potential as a viable second-line or rescue option.

This dataset positions eptinezumab as a differentiated intravenous CGRP therapy with potential clinical utility in treatment-resistant patient cohorts, underscoring its commercial and formulary relevance amid persistent unmet needs in migraine care.

Can eptinezumab provide a meaningful clinical alternative for patients who fail first-line CGRP preventive treatments?

For patients with high disease burden and limited response to subcutaneous CGRP inhibitors, real-world treatment options remain poorly defined. The INFUSE study, which enrolled participants through 100-plus Vyepti Infusion Network sites across the United States, targets precisely this unmet space. All 111 patients included in the analysis had failed at least one preventive anti-CGRP therapy due to lack of effectiveness or tolerability.

After two eptinezumab infusions, nearly 44 percent of participants reported at least a 50 percent reduction in monthly headache days, down from a baseline of 20 days. A subset—26 percent—achieved more than 75 percent reduction. These results stand out given the high baseline severity and prior drug failures, signaling that switching to intravenous administration may offer a pathway for deeper, more durable response in refractory patients.

In addition to migraine frequency reduction, participants experienced an average increase of over six additional “good days” per month, as defined by patient-reported outcomes. Importantly, 75.7 percent reported some level of improvement on the Patient Global Impression of Change scale, with 44.1 percent rating themselves as “much improved” or “very much improved.”

Taken together, these data suggest that eptinezumab may deserve earlier consideration in the treatment pathway, rather than being reserved solely for patients who cycle through multiple subcutaneous or oral options.

How does Lundbeck’s intravenous CGRP strategy compare with subcutaneous competitors in migraine care?

Unlike other CGRP-targeting therapies such as AbbVie’s Qulipta (atogepant), Amgen’s Aimovig (erenumab), or Pfizer’s Nurtec ODT (rimegepant), Lundbeck’s Vyepti is the only therapy in the class designed for intravenous administration. This route enables rapid onset of action—benefits seen as early as Day 1 post-infusion in the PROMISE-1 and PROMISE-2 trials—and ensures 100 percent bioavailability, an advantage in patients with refractory disease.

While subcutaneous options dominate market share due to their convenience and at-home administration, their effectiveness in patients who have already failed another CGRP pathway agent remains modest. Clinical data for switching between subcutaneous anti-CGRPs has historically shown inconsistent outcomes. INFUSE offers the first robust signal that IV delivery may yield meaningfully better responses in this difficult-to-treat population.

From a payer and reimbursement standpoint, the implications are significant. Payers often require step-through of cheaper oral or SC therapies before approving more resource-intensive options. However, if eptinezumab proves consistently effective in switch-resistant cohorts, Lundbeck may find stronger footing to negotiate for earlier line use, particularly among neurologists dealing with high-burden patients.

What are the risks or limitations of real-world adoption for Vyepti in treatment-resistant migraine populations?

Despite its promising six-month outcomes, INFUSE remains an observational study without randomization or comparator arms. No safety data were collected within the study protocol, although adverse events were tracked through routine pharmacovigilance. While this limitation is typical of real-world evidence designs, it may leave payers and guideline committees hesitant to draw strong conclusions.

Another challenge is the logistics of IV administration. Unlike at-home injectables, eptinezumab requires access to infusion centers, which can pose geographic and scheduling barriers—especially in rural or underserved areas. While Lundbeck’s Vyepti Infusion Network aims to mitigate this, expansion will be necessary to make the treatment viable at national scale.

In addition, the total number of participants who had reached the six-month endpoint at the time of data cut (n=111) remains relatively small. Larger and longer-term real-world cohorts will be needed to confirm whether the observed improvements are durable over time and reproducible in more diverse patient populations.

Why does this study mark a potential inflection point in real-world migraine treatment strategy?

The INFUSE study is not just an academic exercise—it reflects a broader shift in how real-world data is being leveraged to refine treatment strategies beyond clinical trial environments. With Vyepti already approved in over 30 markets and positioned as a second- or third-line preventive, Lundbeck’s evidence-generation approach is likely aimed at reshaping that label-to-practice gap.

The timing also matters. CGRP therapies are now mainstream in migraine prevention, yet real-world gaps persist, especially for patients who do not respond to first-line agents. INFUSE may offer a route to solidify eptinezumab as the go-to rescue therapy, not just an afterthought for late-stage cases.

Additionally, if Lundbeck continues to publish outcomes at the nine- and twelve-month marks from this same cohort, and if trends remain consistent, it could build a case for label expansions or even pathway repositioning via updated treatment guidelines.

How does this development influence peer strategies in the competitive migraine market?

If eptinezumab gains traction in refractory populations, competitors may feel pressure to follow suit with head-to-head comparisons or seek combination regimens to enhance outcomes. Some may even consider investigating IV or alternative delivery methods.

AbbVie, which has consolidated its position in the migraine market through multiple assets including Ubrelvy and Qulipta, may face pressure to differentiate on tolerability and first-line effectiveness to maintain share in earlier-stage patients. Pfizer’s Nurtec and Amgen’s Aimovig may also need to explore how they position their SC offerings against a potential migration of late-stage patients toward IV alternatives.

At the same time, newer players or biosimilar entrants could see opportunity in underserved access models—offering CGRP therapy with faster or cheaper infusion protocols if Lundbeck’s success opens this segment.

Ultimately, the INFUSE data highlights that success in the migraine market is increasingly tied to post-approval lifecycle management and real-world differentiation—not just clinical trial superiority.

What does Lundbeck’s INFUSE real‑world data on Vyepti mean for competitors, payers, and the future of migraine treatment?

• Lundbeck’s six-month INFUSE study data shows Vyepti may offer real-world benefit for patients who failed previous preventive anti-CGRP treatments.

• 44.1 percent of patients reported a ≥50 percent reduction in monthly headache days after two infusions of eptinezumab.

• Nearly 76 percent of participants reported some level of improvement in migraine burden using patient-reported outcomes.

• Real-world data supports potential repositioning of Vyepti as a second-line or rescue therapy, not just last-resort.

• Eptinezumab’s intravenous delivery may offer efficacy advantages but raises access and logistical hurdles in clinical practice.

• No safety data were collected under the INFUSE protocol, although standard reporting mechanisms were used.

• Lundbeck may use these results to argue for earlier use of Vyepti in treatment pathways and payer coverage criteria.

• Competitors like AbbVie, Amgen, and Pfizer may need to defend their SC therapies with new switching data or explore alternative formats.

• The INFUSE study signals a broader industry shift toward real-world evidence as a post-market weapon for positioning.

• Migraine treatment strategies may increasingly segment between convenient first-line options and more intensive rescue modalities.